Detail akcie Xinhua Pharm online

Business Summary: SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Company’s main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Shandong Xinhua Pharmaceutical Co Ltd revenues decreased 6% to RMB2.47B. Net income decreased 6% to RMB141.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Research & Development Expense increase of 27% to RMB141.9M (expense), Interest Income decrease of 22% to RMB2.9M (income).